Martin P. Bedigian

1.4k total citations
15 papers, 680 citations indexed

About

Martin P. Bedigian is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Molecular Biology. According to data from OpenAlex, Martin P. Bedigian has authored 15 papers receiving a total of 680 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Cardiology and Cardiovascular Medicine, 6 papers in Endocrinology, Diabetes and Metabolism and 3 papers in Molecular Biology. Recurrent topics in Martin P. Bedigian's work include Renin-Angiotensin System Studies (6 papers), Blood Pressure and Hypertension Studies (5 papers) and Receptor Mechanisms and Signaling (3 papers). Martin P. Bedigian is often cited by papers focused on Renin-Angiotensin System Studies (6 papers), Blood Pressure and Hypertension Studies (5 papers) and Receptor Mechanisms and Signaling (3 papers). Martin P. Bedigian collaborates with scholars based in United States, Switzerland and France. Martin P. Bedigian's co-authors include Alan H. Gradman, YannTong Chiang, Juerg Nussberger, R. Lins, Roland E. Schmieder, Jiakun Zhang, Joel M. Neutel, Yao Sun, Li Lu and Karl T. Weber and has published in prestigious journals such as Circulation, Journal of the American College of Cardiology and Radiology.

In The Last Decade

Martin P. Bedigian

13 papers receiving 640 citations

Peers

Martin P. Bedigian
Benjamin J Epstein United States
Martin P. Bedigian
Citations per year, relative to Martin P. Bedigian Martin P. Bedigian (= 1×) peers Benjamin J Epstein

Countries citing papers authored by Martin P. Bedigian

Since Specialization
Citations

This map shows the geographic impact of Martin P. Bedigian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin P. Bedigian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin P. Bedigian more than expected).

Fields of papers citing papers by Martin P. Bedigian

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin P. Bedigian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin P. Bedigian. The network helps show where Martin P. Bedigian may publish in the future.

Co-authorship network of co-authors of Martin P. Bedigian

This figure shows the co-authorship network connecting the top 25 collaborators of Martin P. Bedigian. A scholar is included among the top collaborators of Martin P. Bedigian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin P. Bedigian. Martin P. Bedigian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Ayalasomayajula, Surya, Ching‐Ming Yeh, Sujata Vaidyanathan, et al.. (2008). Effects of Aliskiren, a Direct Renin Inhibitor, on Cardiac Repolarization and Conduction in Healthy Subjects. The Journal of Clinical Pharmacology. 48(7). 799–811. 14 indexed citations
2.
Watzinger, Norbert, Gunnar Lund, Maythem Saeed, et al.. (2005). Myocardial blood flow in patients with dilated cardiomyopathy: Quantitative assessment with velocity‐encoded cine magnetic resonance imaging of the coronary sinus. Journal of Magnetic Resonance Imaging. 21(4). 347–353. 30 indexed citations
3.
Serra, Denise, Melton B. Affrime, Martin P. Bedigian, et al.. (2005). QT and QTc Interval With Standard and Supratherapeutic Doses of Darifenacin, a Muscarinic M3 Selective Receptor Antagonist for the Treatment of Overactive Bladder. The Journal of Clinical Pharmacology. 45(9). 1038–1047. 48 indexed citations
4.
Gradman, Alan H., Roland E. Schmieder, R. Lins, et al.. (2005). Aliskiren, a Novel Orally Effective Renin Inhibitor, Provides Dose-Dependent Antihypertensive Efficacy and Placebo-Like Tolerability in Hypertensive Patients. Circulation. 111(8). 1012–1018. 377 indexed citations
5.
Wood, Jeanette M., Randy L. Webb, Frédéric Cumin, Christian Schnell, & Martin P. Bedigian. (2004). 1085-165 Aliskiren, a novel, orally effective nonpeptide renin inhibitor, lowers blood pressure after once-daily dosing in marmosets, rats and humans. Journal of the American College of Cardiology. 43(5). A481–A482.
6.
Sun, Yao, et al.. (2004). Tissue angiotensin II in the regulation of inflammatory and fibrogenic components of repair in the rat heart. Journal of Laboratory and Clinical Medicine. 143(1). 41–51. 71 indexed citations
7.
Behr‐Roussel, Delphine, Diane Gorny, Sandrine Compagnie, et al.. (2004). Erectile dysfunction: an early marker for hypertension? A longitudinal study in spontaneously hypertensive rats. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 288(1). R276–R283. 58 indexed citations
8.
Lund, Gunnar, Norbert Watzinger, Maythem Saeed, et al.. (2003). Chronic Heart Failure: Global Left Ventricular Perfusion and Coronary Flow Reserve with Velocity-encoded Cine MR Imaging: Initial Results. Radiology. 227(1). 209–215. 30 indexed citations
9.
Watzinger, Norbert, Gunnar Lund, Maythem Saeed, et al.. (2003). Myocardial blood flow in patients with dilated cardiomyopathy: Quantitative assessment with velocity-encoded cine magnetic resonance imaging of the coronary sinus. Journal of the American College of Cardiology. 41(6). 442–442.
10.
Falk, Sandor, Raphael A. Nemenoff, Howard D. Weinberger, et al.. (2002). Effects of Angiotensin Receptor Blockade on Haemodynamics and Gene Expression after Myocardial Infarction. Drugs in R&D. 3(4). 239–249. 3 indexed citations
11.
Neutel, Joel M. & Martin P. Bedigian. (2000). Efficacy of valsartan in patients aged ≥65 years with systolic hypertension. Clinical Therapeutics. 22(8). 961–969. 23 indexed citations
12.
Bedigian, Martin P.. (2000). Baseline characteristics of the hypertensive cohort of the appropriate blood pressure control in diabetes trial-part 2 with valsartan (ABCD-2V). American Journal of Hypertension. 13(6). S56–S57. 5 indexed citations
14.
Bedigian, Martin P.. (2000). Improving the prognosis of diabetic patients: Evaluating the role of intensive versus moderate blood pressure control with selective angiotensin II receptor blocker (ARB) therapy. Journal of the Renin-Angiotensin-Aldosterone System. 1(2_suppl). 25–28. 5 indexed citations
15.
Bedigian, Martin P., et al.. (1999). Mechanism of action of angiotensin-receptor blocking agents. Current Hypertension Reports. 1(4). 289–295. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026